Visual-Interactive LINE Chatbot / Non Small Cell Lung Cancer · Interventional Study

Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung Cancer

ClinicalTrials.gov · August 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registered randomized controlled trial (not yet recruiting) designed to evaluate a visual interactive LINE chatbot for supporting self-management of EGFR-TKI-related side effects in patients with advanced non-small-cell lung cancer. The primary endpoint is self-management ability measured by the PAM-13 scale at baseline and 1, 3, and 6 months post-intervention. No results are yet available in this registry record; the trial's actual contribution to evidence will depend on its conduct, completion, and reporting of outcomes.

What was studied

Interventional, Randomized, Parallel, Open label, Supportive Care purpose. Non-Small Cell Lung Cancer; age from 18 Years. Intervention: LINE Chatbot Intervention Group. Compared with: usual care — No Intervention. n = 178. National Taiwan University Hospital (Taiwan).

Key findings

Safety

Primary outcome is self-management ability (a surrogate), not clinical outcomes such as symptom control, quality of life scores, or adverse event rates.

Who this may help

This study is not yet recruiting and has reported no results. Clinicians should await completion and publication of results before considering evidence on the efficacy of chatbot-based self-management support in this population.

Plain-language summary

This is a registered but not-yet-recruiting interventional trial with a planned behavioral intervention and surrogate endpoint (self-management ability); no results are available.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Self-Management Ability（PAM-13） (assessed at at baseline and at 1, 3, and 6 months post-intervention)

DesignInterventional, Randomized, Parallel, Open label, Supportive Care purpose

PopulationNon-Small Cell Lung Cancer; age from 18 Years

Sample size178

InterventionLINE Chatbot Intervention Group

Comparatorusual care — No Intervention

SettingNational Taiwan University Hospital (Taiwan)

Reported figures

Quoted from the source exactly as published.

Estimated sample size178

Primary outcome measureSelf-Management Ability (PAM-13)

Assessment timepointsBaseline, 1 month, 3 months, 6 months post-intervention

Study typeInterventional (randomized controlled trial)

InterventionUsual care plus visual-interactive LINE chatbot with visualized and interactive educational content for symptom monitoring and self-care

Clinical bottom line

Caveats

Registry record only; no results are posted or available.
Primary outcome is self-management ability (a surrogate), not clinical outcomes such as symptom control, quality of life scores, or adverse event rates.
Study has not yet begun recruitment; timeline to completion and publication is unknown.
Comparator (usual care alone) and secondary outcomes (quality of life, satisfaction) are described but no outcome data are reported.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Randomized controlled trial design stated; phase NA, behavioral intervention.

Directness

moderate

Primary outcome is self-management ability (PAM-13), a surrogate for clinical benefit.

Consistency

insufficient

No results posted; consistency cannot be assessed.

Risk of bias

insufficient

Registry record only; methods, blinding, and analysis plan not fully described.

Sample adequacy

moderate

Estimated enrollment 178 participants; adequacy depends on unreported effect size assumptions.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07310589). This is a study registration, not published results. Lead sponsor: National Taiwan University Hospital. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 178 participants (ESTIMATED). Conditions: Non-Small Cell Lung Cancer. Interventions: BEHAVIORAL: Visual-Interactive LINE Chatbot. Primary outcome measures: Self-Management Ability（PAM-13） , at baseline and at 1, 3, and 6 months post-intervention. Brief summary: This study aims to evaluate a visual interactive LINE chatbot designed to support self-management of treatment-related side effects among patients with advanced lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. Patients receiving EGFR-TKI treatment often experience long-term side effects that require ongoing self-management. In this randomized controlled trial, participants will be assigned to receive either usual care alone or usual care plus access to the LINE chatbot intervention, which provides visualized and interactive educational content for symptom monitoring and self-care. The primary outcome of this study is self-management ability related to EGFR-TKI-associated side effects. Secondary outcomes include quality of life during treatment and overall satisfaction with the LINE chatbot intervention.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

National Taiwan University HospitalNCT07310589Visual-Interactive LINE ChatbotNon Small Cell Lung Cancer